Buy this ASX 200 company as its costs are actually falling: Firetrail

Rampant inflation means almost every company has to grapple with higher expenses. But here's an exception.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In an era of high inflation, most businesses are having to deal with more expensive supply costs.

So you might be surprised to find a S&P/ASX 200 Index (ASX: XJO) company that is enjoying falling input costs.

And investors could surmise that will be a competitive advantage.

The team at Firetrail thinks CSL Limited (ASX: CSL) is precisely in this enviable position.

'Counter-cyclical nature' of this input cost

One of the big activities for CSL is the collection of blood plasma. While paying donors is illegal in Australia, in the US that is the norm.

The Firetrail analysts' interest in the biotechnology giant piqued recently when it heard a juicy tidbit from a plasma collection rival.

"At its June 2022 result, CSL's competitor Takeda Pharmaceutical Co Ltd (TYO: 4502) announced that the fees it pays to plasma donors have reduced by 15% per litre," read their memo to clients.

During the first couple of years of the COVID-19 pandemic, donor numbers plunged as communities were locked down or people were reluctant to physically visit donation centres.

This meant that donor compensation was raised to provide a higher incentive, and to compete with "substantial levels of fiscal stimulus".

But now as the US shifts to post-COVID life, these fees can be reduced.

"We could see that reverse now that household budgets are becoming more stretched," said the Firetrail team.

"The counter-cyclical nature of this cost driver is one of the key underpinnings to our positive investment thesis on CSL."

2022 bad, 2023 good

The Firetrail team is not the only one bullish on CSL's future.

The CSL share price on Wednesday morning plunged 4.8% after it released its financial results, which saw net profit fall for the 2022 financial year.

But both S&P Global Ratings and Moody's cited the pending growth in plasma collections as a major tailwind for financial year 2023.

"Significant growth in the volume of plasma collected mitigates any concern around inventory, despite higher donor costs," said Moody's Investors Service vice president Ian Chitterer.

"The influenza business continues to perform strongly with record sales once again over the year."

CSL shares are up just 0.38% for the year-to-date. It is still yet to re-touch its pre-COVID highs.

Motley Fool contributor Tony Yoo has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

1 ASX stock to consider buying that could be the next ResMed

There are obviously no guarantees in the share market. But if you're willing to take on some risk, the rewards…

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Healthcare Shares

Why this ASX biotech stock could rise a massive 40%

Bell Potter sees big returns on the cards for investors from this speculative stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Is this announcement the real reason for the rise?

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

GLP-1 obesity medicines do the opposite of what ResMed stock investors feared

Internal research from ResMed provides some surprising news for investors on the impact of GLP-1s.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Guess which ASX AI stock rocketed 170% on an AstraZeneca update

Investors are loving this company's announcement on Wednesday.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Guess which ASX All Ords company is being sued by shareholders over stock price losses

Some of this biotech's shareholders aren't happy with management.

Read more »